MSMO1 and metabolic syndrome: For instance, genetic polymorphisms in CRABP2 are associated with changes in plasma cholesterol levels [62], SNPs in LPL and LASS4 are associated with dyslipidemia [63–65], changes in expression levels of HMGCS1, LDLR and SC4MOL correlated with obesity-related type 2 diabetes and cardiovascular diseases [66].